Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2025-07-20

Clinical Trial Update: Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial of QRX003 Lotion for Netherton Syndrome is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • QRX003 Lotion

Snippet

Sponsor: Quoin Pharmaceuticals | Conditions: Netherton Syndrome | Phase 2, Phase 3 | Status: RECRUITING